COMMUNIQUÉS West-GlobeNewswire

Plumbers Local Union 130 UA Selects Cerner to Manage Health Center for Members
29/10/2018
CHICAGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Plumbers Local Union 130 United Association (UA) announced it has selected Cerner, a global leader in health care technology, to operate a health center in the southwest [...]
Premier Biomedical, Inc.’s CEO Discusses a Bright Future for His Company and All-Natural Solutions with Uptick Newswire’s Stock Day Podcast
29/10/2018
PHOENIX, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Premier Biomedical, Inc. (OTCQB: BIEI ) (“Company”) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of [...]
Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease
29/10/2018
Cocrystal Lithium-Based Therapy, “LiProSal™” Targets the Reduction of Agitation in Patients with AD Salt Lake City, UT, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced [...]
Arch Biopartners Provides Toxicology Update for Metablok
29/10/2018
TORONTO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF) today provided an update on the general results from toxicology and pharmacology studies [...]
Teladoc Health to Participate in Upcoming Investor Conferences
29/10/2018
PURCHASE, NY, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Teladoc Health , Inc. (NYSE: TDOC), the global leader in virtual care, announced today that Jason Gorevic, chief executive officer, and Mark Hirschhorn, chief operating [...]
Onconova Therapeutics to Meet with Potential Investors and Business Development Partners at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark
29/10/2018
NEWTOWN, Pa., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary [...]
BLVD Announces New Chairman; Unveils Plan for Marijuana Revenue Growth; Executes LOI for a Marijuana Related Acquisition
29/10/2018
Posts Second Quarter Financials; Reports an Increase In Cash, Positive Net Income, Cash Flow NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ALL FIGURES IN CANADIAN [...]
Acer Therapeutics Submits NDA for EDSIVO™ for the Treatment of vEDS
29/10/2018
Requests Priority Review NEWTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for [...]
Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018
29/10/2018
Management to host conference call WALTHAM, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to [...]
Avadel Presents Data on Quality of Life Improvement in Patients on NOCTIVA™ at American Urological Association Western Annual Meeting
29/10/2018
Patients treated with NOCTIVA were three times more likely to report no difficulty getting enough sleep and five times more likely to report no bother due to nocturia DUBLIN, Ireland, Oct. 29, 2018 (GLOBE NEWSWIRE) -- [...]
BioDelivery Sciences Announces Changes to its Executive Leadership Team
29/10/2018
James Vollins joins the Company in role of General Counsel, Chief Compliance Officer, and Corporate Secretary Ernest De Paolantonio, Chief Financial Officer announces plan to retire by mid-2019 Scott Plesha, President [...]
Aura Closes $400,000 Convertible Debenture Offering
29/10/2018
TORONTO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Aura Health Inc. (the " Company " or “ Aura ”) ( CSE: BUZZ ) is very pleased to announce that it has closed a non-brokered private placement offering (the “ Offering ”) on [...]
Aptinyx to Present Preclinical Data on Novel NMDA Receptor Modulators for Pain and Cognition at the 48th Annual Meeting of the Society for Neuroscience
29/10/2018
EVANSTON, Ill., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today [...]
Opiant Pharmaceuticals Appoints Seasoned Pharmaceutical Executive Craig Collard to Board of Directors
29/10/2018
SANTA MONICA, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, [...]
Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 8
29/10/2018
REHOVOT, Israel, and BRIDGEWATER, N.J., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and [...]
Physeon Receives Institutional Review Board Approval to Commence US "VIVA" Trial for Veinplicity
29/10/2018
Recent Clinical Study Indicated Device had a Dilatory Effect 38% Greater than other Common Approaches for Veins Targeted for IV Access. Other studies indicate a First IV Stick Success Much Greater Than the Standard of [...]
Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER
29/10/2018
STOUGHTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the publication of “Evaluation of the oral human abuse potential of Oxycodone DETERx ® formulation ( [...]
Eidos Therapeutics to Host Conference Call and Webcast to Discuss Phase 2 Clinical Trial Results
29/10/2018
SAN FRANCISCO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics , Inc. (Eidos) (Nasdaq:EIDX) today announced that management will host a conference call and webcast to discuss the results of its Phase 2 clinical [...]
Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP
29/10/2018
– Met primary endpoint of Early Clinical Response at 96 hours after the first dose – – Supplemental NDA expected to be filed with FDA in 1H 2019 – – Baxdela currently FDA approved for treatment of adult patients with [...]

Pages